Sr. Vice President and CFO of Medivation Inc. (MDVN, Financial) Clarence Patrick Machado sells 20,000 shares of MDVN on 12/07/2009 at an average price of $33.27 a share.
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices Medivation Inc. has a market cap of $1.11 billion; its shares were traded at around $33.25 with and P/S ratio of 88.6.
MDVN is in the portfolios of George Soros of Soros Fund Management LLC.
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices Medivation Inc. has a market cap of $1.11 billion; its shares were traded at around $33.25 with and P/S ratio of 88.6.
MDVN is in the portfolios of George Soros of Soros Fund Management LLC.
Insiders' Positions with MDVN
- Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 09/10/2009 at the average price of 25.84, the price of the stock has increased by 28.68% since
- Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 07/01/2009 at the average price of 22.62, the price of the stock has increased by 46.99% since
Insiders' Positions with MDVN
- Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 11/11/2009 at the average price of 28.28, the price of the stock has increased by 17.57% since
- Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 09/10/2009 at the average price of 25.86, the price of the stock has increased by 28.58% since
- Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 07/01/2009 at the average price of 22.48, the price of the stock has increased by 47.91% since
Insiders' Positions with MDVN
- Sell:: Director Gregory Bailey sold 10,000 shares of MDVN stock on 12/01/2009 at the average price of 31.49, the price of the stock has increased by 5.59% since
- Sell:: Director Gregory Bailey sold 14,000 shares of MDVN stock on 11/20/2009 at the average price of 25.99, the price of the stock has increased by 27.93% since
- Sell:: Director Gregory Bailey sold 14,000 shares of MDVN stock on 11/20/2009 at the average price of 29, the price of the stock has increased by 14.66% since
- Sell:: Director Gregory Bailey sold 10,000 shares of MDVN stock on 09/14/2009 at the average price of 25.99, the price of the stock has increased by 27.93% since
- Sell:: Chief Medical Officer Lynn Seely sold 18,000 shares of MDVN stock on 09/10/2009 at the average price of 25.87, the price of the stock has increased by 28.53% since
